Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10 in San Diego, CA. The posters include the company’s first public disclosure of data validating its RNA-targeting platform for designing small molecules to bind dir